Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for ACB, LVS and ICPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Tuesday, 24 November 2020 06:20 AM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ACB Shareholders Click Here: https://www.zlk.com/pslra-1/aurora-cannabis-inc-loss-submission-form?prid=11166&wire=1
LVS Shareholders Click Here: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=11166&wire=1
ICPT Shareholders Click Here: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11166&wire=1

* ADDITIONAL INFORMATION BELOW *

Aurora Cannabis Inc. (NYSE:ACB)

ACB Lawsuit on behalf of: investors who purchased February 13, 2020 - September 4, 2020
Lead Plaintiff Deadline : December 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aurora-cannabis-inc-loss-submission-form?prid=11166&wire=1

According to the filed complaint, during the class period, Aurora Cannabis Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Las Vegas Sands Corp. (NYSE:LVS)

LVS Lawsuit on behalf of: investors who purchased February 27, 2016 - September 15, 2020
Lead Plaintiff Deadline : December 21, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=11166&wire=1

According to the filed complaint, during the class period, Las Vegas Sands Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

ICPT Lawsuit on behalf of: investors who purchased September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline : January 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11166&wire=1

According to the filed complaint, during the class period, Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: